Poland· PL-100033315

Ketosteril

A blood and related products product containing preparat złożony, registered in Poland by Fresenius Kabi Deutschland GmbH.

ATC B05A

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedKetosterilATCB05AREGISTER NO.PL-100033315PACKS LISTED2CHECKEDSeptember 27, 2026

The record

At a glance

URPL (Poland)
Active substance
Preparat złożony
Manufacturer
Fresenius Kabi Deutschland GmbH
Country
Poland (PL)
ATC code
B05A
ATC class
BLOOD AND RELATED PRODUCTS
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    05909990338511
  • gtin
    05909991472696

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b81a27af-83d1-4543-96e2-595b2f0f94d6
GET /v1/drugs/b81a27af-83d1-4543-96e2-595b2f0f94d6?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "-",
  "packaging": "05909990338511 ¦ Rp ¦ 5224\n100 tabl.\n05909991472696 ¦ Rp ¦ 142986\n300 tabl.",
  "substance": "L-Lysini acetas 105 mg + L-Threoninum 53 mg + L-Tryptophanum 23 mg + L-Histydyna 38 mg + L-Tyrosinum 30 mg",
  "common_name": "Preparat złożony",
  "pl_product_id": "100033315",
  "pozwolenie_nr": "03385",
  "auth_procedure": "NAR",
  "authorisation_validity": "Bezterminowe"
}

See everything about preparat złożony.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.